Thrombophilia work-up and clinical outcomes in Indian patients with unprovoked venous and arterial thrombosis aged 18-50 years | BTVB Bioequivalence of von Willebrand factor-containing concentrates: implications for von Willebrand disease | BTVB Cardiovascular risk in hormone replacement therapy | BTVB Direct oral anticoagulants: does one dose fit all? Why, when and how testing | BTVB Cardiovascular risk profile evolution over 15 years: CV-PREVITAL vs Moli-sani Study | BTVB Launch of National Registry for Congenital Hematological Disorders in Palestine: Haemo-PAL | BTVB
Skip to main content Skip to main navigation menu Skip to site footer
Bleeding, Thrombosis and Vascular Biology

Editor-in-Chief: Giovanni de Gaetano, Italy | eISSN: 2785-5309

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Archives
  • Copyright
  • Supplements
    • ICTHIC 2026
    • SISET 2025
    • ICTHIC 2024
  • Register
  • Login
  • Search
  • Contacts
0.5
Impact Factor 2025
0.6
CiteScore 2025
This journal has not published any issues.
0.5
Impact Factor 2025
0.6
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • Anticoagulation in obese patients: challenges and strategies

    Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia
    18-09-2025
    https://doi.org/10.4081/btvb.2025.174
    2015
    PDF: 519
    HTML: 302
    XML: 185
  • The key to fibrinolysis and thrombolysis

    Roger Lijnen, Désiré Collen
    09-09-2025
    https://doi.org/10.4081/btvb.2025.368
    1675
    PDF: 517
    HTML: 260
  • PO53 | Effectiveness and safety of DOACS in patients with renal transplantation A. Ierardi, A. Strangio, M. Leotta, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU Renato Dulbecco, Catanzaro, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.322
    627
    PDF: 16
  • Pharmacokinetic interactions between anticancer drugs and direct oral anticoagulants: clinical implications for safe anticoagulation

    Tzu-Fei Wang, Kristen M. Sanfilippo, Marc Carrier
    16-04-2026
    https://doi.org/10.4081/btvb.2026.434
    322
    PDF: 173
  • PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.339
    615
    PDF: 21
  • PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.313
    630
    PDF: 18
  • PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | 1Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; 2Hull York Medical School, Hull, UK; 3Academic Library Services, University of Hull, UK; 4NHS Humber Health Partnership, Hull, UK

    ICTHIC 2026
    16-04-2026
    https://doi.org/10.4081/btvb.2026.552
    491
    PDF: 113
  • PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA

    ICTHIC 2026
    16-04-2026
    https://doi.org/10.4081/btvb.2026.523
    548
    PDF: 100
  • PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany

    ICTHIC 2026
    16-04-2026
    https://doi.org/10.4081/btvb.2026.522
    416
    PDF: 95
  • Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

    Ezio Zanon, Giancarlo Castaman, Augusto Bramante Federici, Maria Elisa Mancuso, Gianfranco Pasut, Alberto Tosetto, Angiola Rocino, Rita Carlotta Santoro
    26-01-2026
    https://doi.org/10.4081/btvb.2026.415
    1256
    PDF: 336
    HTML: 163
  • Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

    Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz
    16-05-2024
    https://doi.org/10.4081/btvb.2024.118
    1886
    PDF: 1297
  • Factor XI inhibitors in cancer-associated venous thromboembolism: what’s next?

    Hiranya M. Dave, Mehrie H. Patel, Keith R. McCrae, Alok A. Khorana
    16-04-2026
    https://doi.org/10.4081/btvb.2026.424
    310
    PDF: 183
  • PO78 | Acquired hemophilia A as a paraneoplastic syndrome: two cases report on a rare coexistence M. Gagliardi, L. Capone, A. Ciampa | Centro Emostasi, AORN Moscati, Avellino, Italy

    22-10-2025
    https://doi.org/10.4081/btvb.2025.347
    619
    PDF: 18
1 - 13 of 13 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article
  • Index of Authors

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review
Vol. 5 No. 3 (2026): In memory of Armando...
Trypsin is as procoagulant as factor XIIa
Stephanie A. Smith et al.
28 August 2026
Vol. 5 No. 3 (2026): In memory of Armando...
Inflammation and hemostatic system: a selection of involved clinical disorders
Francesco Marongiu et al.
28 August 2026
Vol. 5 No. 4 (2026)
Von Willebrand Disease (VWD) 100 years after its first description: the research of Italian investigators for a better management of VWD patients
Augusto B. Federici et al.
9 October 2026
Vol. 5 No. 4 (2026)
Platelets versus monocytes as cellular sources of blood-borne tissue factor: a quantitative and functional comparison in healthy subjects...
Marina Camera et al.
12 October 2026

indexing

INDEXING
  • Scopus
  • Web of Science
  • DOAJ
  • Google Scholar
  • OpenAlex
  • Analytics

Keywords

Bleeding, Thrombosis and Vascular Biology

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

eISSN: 2785-5309

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors
Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.